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AraC �elongs among �iologically active antime-
ta�olites that are structural analogues of naturally 
occurring intracellular meta�olic intermediates es-
sential for the normal function of a cell. AraC as such 
is an antimeta�olite of deoxycytidine and cytidine and 
serves as a su�strate for some intracellular enzymes 
utilizing deoxycytidine and cytidine as a su�strate. 
This ultimately results in the inhi�ition of key enzymes 
necessary for synthesis of �iological macromolecules�� 
mainly of �NA. Ara-C is �eing used in the treatment 
of hematological malignancies�� usually in com�ined 
chemotherapy [1�5]. It acts through inhi�ition of �NA 
and RNA synthesis as well as reparative �NA synthesis. 
Intracellular activation of araC is required for its cyto-
toxic and therapeutic effects. Ara-C is �eing activated 
to a therapeutically active form�� ara-C-triphosphate 
�ara-CTP�� which inhi�its �NA synthesis and induces 
apoptosis [����]. The extensive inactivation of ara-C in 
clinical situations represents a significant limit for the 
therapeutic outcome. Ara-C is deaminated to its inac-
tive meta�olite ara�inofuranosyluracil �ara-U���� which 
is caused �y cytidine deaminase [��11]. Because of 
this pro�lem�� synthesis of many ara-C analogs that 
are more sta�le towards deamination was performed 
[for example1��� 1�].
In order to enhance the cytotoxic effects of ara-C�� 
a strategy of masking ara-C �y the synthesis of a con-
jugate with another molecule [14�17] was employed in 
this work. This is expected to increase the efficacy ara-
C and might also �e a�le to overcome drug resistance 
which still remains the major pro�lem in cancer che-
motherapy [1����]. Additionally�� pharmacokinetic and 
pharmacodynamic properties of ara-C are also altered 
[1��� �1�� ��]. The molecule selected for the preparation 
of conjugates with ara-C was sulfanilamide [��].
The main goal of this work was to compare the 
cytotoxic/therapeutic activity of ara-C with these of 
sulfanilamide conjugates. In growth inhi�ition assay�� 
the in vitro activity of the conjugates in L1�1� leukemia 
cell line was compared with the effect of single ara-C 
administration. Employing in vivo experiments�� thera-
peutic potential and acute toxicity of these compounds 
were determined in L1�1�-leukemia �earing mice. 
Again�� these parameters were compared to the data 
o�tained with araC treatment.
Materials and Methods
Synthesis of araC conjugates. Melting points 
were determined on a Stuart Scientific SMP1 melting 
point apparatus and are uncorrected. The Science 
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in araC treatment and between two araC-analogues are most probably caused by slow liberation of araC from both conjugates. We 
are considered that prolonged araC liberation protected them from inactivation and extended the time period of therapeutic action 
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Abbreviations used: araC — cytosine arabinoside; conjugate 
A — 4-Amino-N-[1-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-
furan-2-yl)-4-imino-1,4-dihydro-pyrimidin-2-yl]-benzenesulfon-
amide; conjugate B – 8-(4-Amino-benzenesulfonyl)-5-imino-13-
oxa-2,6,8-triaza-tricyclo[8.2.1.02,7]trideca-3,6-diene-11,12-diol; 
IC50 – drug concentration inducing 50% inhibition of cellular viabili-
ty; MST — mean survival time; ILS — increase of life-span.
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University�� performed all the instrumental analyses. Ele-
mental analyses were determined on LECO elemental 
analyzer CHNS ��� apparatus�� and were within ± �.4% 
of the calculated values. 1H NMR spectra were re-
corded on Bruker �PX 4�� NMR spectrometer using 
�MSO-d�� as solvent and tetramethylsilane �TMS�� 
as an internal reference. The chemical shifts were 
reported in ppm. Infrared �IR�� spectra were recorded 
on Perkin Elmer System ���� FT-IR spectrometer. 
Column chromatography was carried out with silica 
gel �Kieselgel ����� 7����� mesh; Aldrich��. TLC was 
conducted on �.�5 mm precoated silica gel plates 
����F�54�� Merck��.
Synthesis of the conjugate A — 4-Amino-N-
[1-(3,4-dihydroxy-5-hydroxymethyl-tetrahyd-
ro-furan-2-yl)-4-imino-1,4-dihydro-pyrimidin-2-
yl]-benzenesulfonamide. To a solution of 4-amino-
�enzenesulfonamide �1.�� g�� ��.� mmol�� in dimethyl 
formamide �14 ml���� sodium hydride �144 mg�� ��.� mmol�� 
and cyclocytidine hydrochloride �7�4 mg�� �.� mmol�� 
was added with stirring under nitrogen. The reaction 
mixture was stirred at room temperature for ��� min�� 
evaporated and the residue was chromatographed 
on a column of silica gel in the system ethyl acetate: 
acetone: ethanol: water � : 1 : 1: 1 ��5� ml��. Fractions 
of 1� ml were collected and pooled together and con-
centrated on a rotovap. Evaporation of the fractions 
17��1 afforded the compound 1.�7 g as foam. Analyti-
cal sample was o�tained �y crystallization from etha-
nol�� to give �4� mg �71 % yield�� of the title compound. 
mp ��5����� °C. 1H NMR ��MSO-d���� 4�� MHz.�� �� 7.71  
�d�� 1H�� J = 7.5 Hz���� 7.��5 ��road s�� 1H���� 7.��� �d�� �H�� J = 
�.4 Hz���� 7.5� ��road s�� 1H���� ��.4� �d�� �H�� J = �.��� Hz���� 
��.�� �d�� 1H�� J = �.��� Hz���� 5.�7 �d�� 1H�� J = 7.�� Hz���� 5.57 
�s�� �H���� 5.55 ��road d�� �H�� J = 5.� Hz���� 5.�� ��road t�� 
1H�� J = 5.5 Hz���� 4.�� ��road t�� 1H���� �.�� ��road�� 1H���� 
�.7� ��road�� 1H���� �.5� ��road t�� �H�� J = 5.5 Hz��. IR 
�KBr pellet�� cm�1��: �� �4���-��4��� 1��44�� 15�7�� 1551��     
14��7�� 1����� 1�47�� 11����� 1�77. Anal cal: C 15H1�N5O��S. 
This synthesis is �ased on the reported procedure �y 
Novotny et al. [�4].
Synthesis of the conjugate B — 8-(4-Amino-
benzenesulfonyl)-5-imino-13-oxa-2,6,8-triaza-
tricyclo[8.2.1.02,7]trideca-3,6-diene-11,12-diol. 
To a solution of 4-amino�enzenesulfonamide in di-
methyl formamide�� was added ���% sodium hydride 
in mineral ����� mg�� 5.�� mmol�� and 5-chlorocyclocyti-
dine hydrochloride �7�5 mg�� �.� mmol�� is added with 
stirring under nitrogen gas. The mixture was stirred 
at room temperature for ��� min�� evaporated and the 
residue was chromatographed on a column of silica 
gel eluting with ethyl acetate and ethyl acetate — 
ethanol — acetone — water 4 : 1 : 1 : 1. Fractions of 
1� ml were collected and the appropriate fractions 
were pooled and concentrated. Evaporation of the 
fractions 1���� afforded the compound in the as foam�� 
which was triturated in cold ether and dried to give ��� 
mg �7�% yield�� of the title compound. mp 1�����1 °C. 
1H NMR ��MSO-d���� 4��Mhz.�� �� 7.71�7.5� �m�� 4H����    
��.4� �d�� �H�� J = �.4 Hz���� ��.�� �d�� 1H J = �.� Hz���� 5.�� 
�d�� 1H�� J = 7.�� Hz���� 5.77 ��road t�� �H�� J = 4.� Hz���� 5.5� 
��road s�� �H���� 4.���4.��� �m�� 1H���� �.�4��.��� �m�� �H���� 
�.77��.�7 �m�� �H��. IR �KBr pellet�� cm�1��: �� ��54������� 
1��4���� 15�5�� 154��� 14��7�� 1����� 1�5��� 11���� 1�7�. Anal 
cal: C15H17N5O5S. This synthesis is �ased on the re-
ported procedure �y Novotny et al. [�4].
Cell culture. The L1�1� murine leukemia cell line 
was purchased from ATCC �American Type Culture 
Collection�� Manassaa�� VA�� USA��. Cells were maintained 
at �7 °C in RPMI 1��4� medium supplemented with 
1�% heat-inactivated fetal calf serum �GIBCO�� Grand 
Island Biological Co.�� Grand Island�� NY�� USA���� 1�� U/ml 
Penicillin G�� 1�� µg/ml streptomycin�� and � mM L-glu-
tamine �Se�ac�� Germany�� in a humidified atmosphere 
containing 5% CO�. Cells in the logarithmic phase of 
growth were used for all studies descri�ed.
Growth inhibition assay. Exponentially growing 
L1�1� cells ��.� x 1��� per ml�� were incu�ated with in-
creasing concentrations of araC conjugates under cell 
culture conditions. Cytotoxicity was compared to the 
cytotoxicity of araC on an equimolar �ase. Cell counts 
and IC5� values were determined after �4 h. Via�ility 
of cells was determined �y staining with Trypan �lue. 
Results are presented as IC5� values.
Animals. In�red �BA/�J mice of �oth sexes �weigh-
ing 1���� g�� were o�tained from the �reeding facility 
of the Cancer Research Institute of SAS �Bratislava�� 
Slovak Repu�lic��. The animals were reared under 
standard conditions; six mice were housed in a cage. 
Food and water were provided ad libitum. The facility is 
certificated to perform scientific research on animals. 
The Ethics Committee of the Cancer Research Institute 
approved the in vivo experiments. These experiments 
were performed in full adherence with the European 
Community Guidelines principles for the care and use 
of la�oratory animals.
Acute toxicity of drugs. Acute toxicity of the con-
jugates was monitored through registration of �ody 
weight of the experimental animals on daily �asis 
during the whole experiment.
In vivo antileukemic activity. L1�1�-leukemia 
�earing mice were used as antileukemic models 
of therapy [1��� �5�� �5]. The experimental animals 
were intraperitoneally implanted with L1�1� leukemia 
cells �1 x 1�5 cells per mouse��. The chemotherapy 
was started �4 h later. The drugs were administered 
intraperitoneally ��.5 ml per mouse��. The treatment 
schedule and doses were chosen according to pre-
vious experiments with araC. Animals were weighed 
daily and o�served for the development of ascites and 
leukemia related death. Mean survival time �MST�� and 
percentage of increase of life span �% ILS�� were cal-
culated and compared with MST of untreated control 
groups. Statistical significance of the difference was 
calculated and the effect of the therapeutic regimen 
was evaluated using a standard t-test for unpaired 
o�servations.
Statistical analysis. IC5� values of drugs were 
calculated using the CalcuSyn software for Windows. 
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Statistical significance of the o�tained results was 
determined �y unpaired t-test.
results and discussion
AraC is a drug that is routinely used in treatment of 
hematological malignancies as discussed earlier [15]. 
However�� it is relatively easily deaminated to ara�ino-
syluracil that possesses no therapeutic activity and its 
formation is not �eneficial for a patient [��11]. This 
represents the main o�stacle in its �roader use and 
�etter therapeutic outcomes achieved. Consequently�� 
the attention is �eing paid to synthesis and evaluation 
of anticancer properties of many new ara�inosylcyto-
sine derivatives [�5]�� analogs [����� �7] and conjugates 
[15�� 1���� ��] as well as to innovative therapeutic regimes 
that overcome the pro�lem of deamination and that 
will �enefit patients.
 In our work we attempted to prepare and evaluate 
antileukemic activity of two conjugates of ara�ino-
sylcytosine and sulfanilamide. The very small-scale 
synthesis of these two su�stances was reported earlier 
[�4] �ut their anticancer potential was not properly 
evaluated. The conjugation of sulfonamide moiety to 
nucleoside is interesting �ecause�� potentially�� it should 
result in protection of the araC amino group against 
deamination. Additionally�� it is likely to decrease hy-
drophilicity of araC and increase the life-time of the 
conjugate in the organism thus increasing the time 
of araC actions on leukemia cells. �espite of the fact 
that any anticancer activity of sulfanilamide itself was 
not reported�� sulfonamides as a chemical group are 
known to inhi�it cell proliferation at mitosis [��]�� arrests 
cell cycle in the G1 phase�� inhi�it car�onic anhydrase 
associated with cancer and alters gene expression 
[��]. Some of sulfonamides�� for example celecoxi� 
�4-[5-�4-methylphenyl��-�-�trifluoromethyl��-1H-pyra-
zol-1-yl]�enzene-sulfonamide�� [�1�� ��]�� are already 
recognized for their effects in cancer therapy. More-
over�� the com�ination of nucleoside antimeta�olite 
and sulfonamide in one molecule was justified and our 
expectations were that sulfonamide�� while protecting 
araC moiety against deamination and modifying its 
pharmacokinetic�� may possi�ly contri�ute �y specific 
mechanisms to anticancer activity of araC. This is 
�ecause various mechanisms of anticancer activity 
of sulfonamides are reported in scientific literature�� 
including mediating cell-cycle arrest�� activation of 
caspases and downregulation of COX-� expression 
[��] or interfering with other enzymes�� for example 
with caspase anhydrase [���� �4] or with microtu�ule 
assem�ly dynamics [���� �4] etc.
AraC cytotoxicity and cytotoxicity of �oth araC 
conjugates �A and B�� was determined �y the Trypan 
�lue exclusion method in vitro using L1�1� leukemia 
cells. Ta�le 1 presents results of cytotoxicity study 
expressed as IC5� �µmol/l��. The cytotoxicity decreases 
in the order of araC >> conjugate A > conjugate B. The 
analogue A is ���-times less active and the analogue B 
is 757-times less active than araC. This may �e ex-
pected as the activity of araC part of conjugate can 
�e activated to its active meta�olite araC triphosphate 
only after its releasing from the conjugate.
Microscopic evaluation of cells exposed to tested 
compounds revealed same changes in morphology 
of L1�1� cells�� mainly an increase in their size. This 
supports the hypothesis that the mechanism of cyto-
static/cytotoxic effect of all three tested compounds 
is the same. This is despite of the fact that this effect 
was achieved at different concentrations of all this 
compounds �Ta�le 1��.
Table 1. The cytotoxic activities of araC and two conjugates A and B were 
compared respectively. Relative values represent the lower measure of 
cytotoxic activity of araC conjugates vs araC
IC50 (µmol/l) Relative values
araC 0.06 1-times
A 18.2 303-times
B 45.4 757-times
fig. 1. Chemical formulas of araC — sulfonamide conjugates 
A and B
Because studied compounds exhi�ited different 
toxicity in experiments in vitro�� in experiment in vivo 
the dosage of �oth araC conjugates was increased 
1�-times �compared to araC�� for in vivo experiments 
involving leukemia L1�1�-�earing mice [1��� �5]. The 
application regime was the same for application of 
araC and two of its analogues �5 consequent days��. 
Statistically significant therapeutic outcome was 
o�served with all three therapeutic su�stances. The 
outcome of the therapy was the �est with araC and 
decreased for araC-analogues: araC >> conjugate A > 
conjugate B �Ta�le ���.
Table 2. Therapeutic effect of araC and araC — sulfonamide conjugates A 
and B in leukemia L1210-bearing mice
N Dose/day (µmol/kg)
Schedule 
(days)
Cumulative do-
se (µmol/kg)
Survival 
(days ± SD)
ILS 
(%) P
Control 6 — — — 7.3 ± 1.0 — —
araC 6 40 1, 2, 3, 
4, 5
200 14.2 ± 0.4 95.4 < 0.0001 
A 6 400 1, 2, 3, 
4, 5
2000 10.8 ± 1.9 48.3 0.0028
B 6 400 1, 2, 3, 
4, 5
2000 9.1 ± 0.5 24.3 0.0023
Recorded significantly decreased cytotoxicity of 
araC analogues in in vitro experiment �see Ta�le 1�� 
corresponds well with decreased therapeutic activity 
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of the analogues in vivo �see Ta�le ���. Additionally�� 
the in vitro and in vivo results recorded for two araC 
analogues correspond well. Lower cytotoxicity of the 
conjugate A compared to the cytotoxicity of the conju-
gate B in vitro �~ �.5-times�� is similar to the decreased 
therapeutic outcome in vivo �~ �.�-times��. The diffe-
rence in cytotoxicity �compared to araC and �etween 
two analogues�� is most pro�a�ly caused �y necessary 
li�eration of araC from �oth conjugates. The incorpo-
ration of sulfonamide moiety into the conjugate B �y 
two �onds �see the structural formula�� also explains 
decreased antileukemic activity of the conjugate B 
compared to the conjugate A.
fig. 2. Scheme of chemical synthesis of the araC � sulfonamide 
conjugates A and B. a. Chemical synthesis of the conjugate A. 
b. Chemical synthesis of the conjugate B. 
Additional evaluation of the o�tained results led 
us to the following comparisons: The ration �etween 
therapeutic activity and cytotoxicity �a cumulative 
dose vs IC5��� for araC is ���� �Ta�le ���. This is the 
ratio that characterizes the rate of araC inactivation 
�deamination�� in organism. When the same calculation 
is performed for the conjugate A and for the conjugate 
B�� the ration of therapeutic activity vs cytotoxicity for 
the conjugates investigated is significantly lover �11� 
and 44�� compared to the same parameter o�tained for 
araC �Ta�le ���. Based on this and also on the hypoth-
esis that sulfanilamide as such does not possess any 
anti-cancer activity�� it can �e concluded that the in-
activation/deamination of the conjugate A is ��-times 
lower ����� : 11��� and of the conjugate B is 75-times 
lower ����� : 44�� compared to araC.
Table 3. The ratio of cytotoxicity (IC50) versus antileukemic activity (cumu-
lative doses) for the araC and araC-sulfonamide conjugates A and B was 
assessed in in vitro and in vivo experimental models (data are presented 
in Table 1 and Table 2). The relative values characterize the rate of araC 
inactivation/deamination in organism
Drugs IC50 (µmol/l) Cumulative doses (µmol/kg) Relative values
araC 0.06 200 3333-times
A 18.2 2000 110-times
B 45.4 2000 44-times
It is known that araC as such possesses a very 
low toxicity as documented �y the results presented 
in Fig. �. The weight monitoring of the experimental 
animals during chemotherapy confirmed that the 
used doses of the araC analogues tested �4�� µmol/
kg per day�� were not toxic in the experimental mice 
�see Fig. ���. Our previous experiments revealed that 
4�� µmol of araC/kg per day applied in the regime of 
5 consecutive days is su�lethal �results not shown��. 
The weight monitoring performed during the in vivo 
experiment �during the application of araC and araC 
conjugates�� aimed at registering possi�le toxicity of 
the tested su�stances. This would �e recorded as a 
decrease in the weight of experimental animals. How-
ever�� toxicity was not o�served with any of two tested 
araC analogues. Additionally�� the conjugates A and B 
did not affect any important organ or function in the 
used animals at used dosage. This is an additional 
support for the hypothesis that tested araC conjugates 
retained the same mechanism of antileukemic activity 
as did araC. 
fig. 3. Monitoring of weight of the experimental animals during 
the araC and araC-sulfonamide conjugates A and B application 
as an indicator of toxicity demonstrated �y tested compounds 
In conclusion�� it is demonstrated that araC conju-
gates A and B possess the cytotoxic and therapeutic 
activity similar to araC �ut at significantly higher 
concentrations. This is possi�ly caused �y their high 
intracellular sta�ility. On the other hand�� the inactiva-
tion �deamination�� of the araC moiety of the conjugates 
A and B is also su�stantially decreased compared to 
araC deamination in vivo. Originally�� araC-containing 
analogues were prepared with the aim that they should 
protect araC amino groups towards deamination 
and serve as depot forms of araC. This investigation 
confirmed that araC-conjugation is a suita�le way for 
protecting araC sta�ility.
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ПРОТИВОЛЕЙКЕМИЧЕСКАЯ АКТИВНОСТЬ СУЛЬФОНАМИДНЫХ 
КОНЪЮГАТОВ АРАБИНОЗИЛЦИТОЗИНА
Цитозинарабинозид (araC) и��о��з��т �ри т�ра�ии ������ии и �и��о��, одна�о ��ид� ��о а�ти�но� ��табо�и����о� ина-            
�ти�ации и �и�итиро�анно� а�ти�но�ти �озда�т�я и и���т��а�т�я но��� ана�о�и araC. Цель работ� — �инт�з д��х �онъ-
��ато� araC и оц�н�а их цитото��и����о�/�роти�о������и����о� а�ти�но�ти.      Методы: �инт�з �����она�идн�х �онъ��ато� 
araC A и B �ро�оди�и � б�з�одно� р��и�� � и��о��зо�ани�� 5’-х�орци��оцитидина � �а���т�� и�ходно�о �ат�риа�а. ��я                
�одт��р�д�ния �тр��т�р� и��о��зо�а�и э����нтн�� ана�из, ЯМР, ИК и УФ ����тро��три�. Синт�зиро�анн�� �онъ��а-
т� araC и���т��а�и на цито��и�но�т� �роти� ���то� ������ии �инии L1210         in vitro,  а та��� на на�и�и� т�ра���ти����о� 
а�ти�но�ти и то��и�но�ти in vivo  на ��шах � э����ри��нта��но� о��хо��� L1210. Результаты: цито��и������ а�ти�но�т� 
araC и �онъ��ато� A и B ��ра�а�и �а� IC        50 (µМ/�). Конъ��ат A о�аза��я � 303 раза ��н�� а�ти�н��, а �онъ��ат �� — � 757             
раз ��н�� а�ти��н, ��� araC. �роти�оо��хо����� а�ти�но�т� и о�тр�� то��и�но�т� �о�дин�ни� и����до�а�и � э����ри��н-         
тах in vivo . Стати�ти����и зна�и��� раз�и�ия � т�ра���ти����о� э����ти�но�ти �р��арато� от���а�и �ри ���о�ии, ���и 
доз� �онъ��ато� б��и � 10 раз ��ш�, ��� та�о��� araC. �т����но, �то � то �р��я �а� �оотнош�ни� ���д� цито��и�но�т��          
и т�ра���ти����о� а�ти�но�т�� д�я araC б��о 3333, то д�я �онъ��ато� A и B эта ���и�ина б��а зна�ит���но ни�� (110               
и 44 �оот��т�т��нно), �то ��аз��а�т на то, �то ина�ти�ация �онъ��ато� А и �� araC �рои�ходит � 30 и 70 раз ��д��нн��        
�оот��т�т��нно, ��� ина�ти�ация araC. Выводы: раз�и�ия � цито��и����о� и т�ра���ти����о� а�ти�но�ти araC и �онъ��ато�   
��роятн�� ����о о�р�д��я�т�я ��д��нн�� ����обо�д�ни�� araC, а �родо��ит���н�� �роц��� ����обо�д�ния araC за�и�а�т       
а�ти�но� �����т�о от ина�ти�ации и ����и�и�а�т �родо��ит���но�т� т�ра���ти����о�о д���т�ия �онъ��ато�.
Ключевые слова: арабинози�цитозин, цитарабин, �����ани�а�ид, �онъ��ат, �роти�о������и����ая а�ти�но�т�, ������ия L1210.
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